Press Room
Pipeline of TROP-2-Targeted Immunotherapies
TROP-2: a Blockbuster target with opportunities for new drug modalities – a pipeline review STUTTGART, Germany I August 26, 2025…
Pipeline of Nectin-4-Targeted Immunotherapies
Nectin-4: a clinically and commercially validated target with limited competition – a pipeline review STUTTGART, Germany I August 26, 2025…
Pipeline of CCR8-Targeted Immunotherapies
CCR8: an attractive immuno-oncology target for antibody therapy – a pipeline review STUTTGART, Germany I August 20, 2025 I La…
Pipeline of EpCAM-Targeted Immunotherapies
EpCAM: conditional activation technologies can make EpCAM a viable target – a pipeline review STUTTGART, Germany I August 19, 2025…
Pipeline of 5T4-Targeted Immunotherapies as an example for new service of pipeline evaluations
5T4: a delicate target for sophisticated payload delivery – a pipeline review STUTTGART, Germany I August 19, 2025 I La…
Pipeline of B7-H4-Targeted Immunotherapies
B7-H4: a promising target for effector-enhanced drug modalities – a pipeline review STUTTGART, Germany I August 18, 2025 I La…
Pipeline of Mesothelin-Targeted Immunotherapies
Mesothelin: an old solid tumor target for next generation drug modalities – a pipeline review STUTTGART, Germany I August 18,…
Pipeline of c-Met-Targeted Immunotherapies
c-Met: a well-suited target for payload delivery by antibodies – a pipeline review STUTTGART, Germany I August 15, 2025 I…
Target selection in drug discovery: new standardized service of evaluation of customer-selected targets
STUTTGART, Germany I August 14, 2025 I Selecting the right target remains the most important decision to make in drug…
Pipeline of Her3-Targeted Immunotherapies
STUTTGART, Germany I August 14, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the…
